Ideaya Biosciences Inc IDYA

NAS: IDYA | ISIN: US45166A1025   26/04/2024
39,94 USD (+3,42%)
(+3,42%)   26/04/2024

26 april 2024 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

24 april 2024 · IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study · Persbericht

22 april 2024 · IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer · Persbericht

5 april 2024 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1 april 2024 · IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event · Persbericht

12 maart 2024 · IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer · Persbericht

4 maart 2024 · IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events · Persbericht

20 februari 2024 · IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update · Persbericht

1 februari 2024 · IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events · Persbericht

26 januari 2024 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

7 januari 2024 · IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance · Persbericht

29 december 2023 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 december 2023 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 december 2023 · IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event · Persbericht

4 december 2023 · IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer · Persbericht

3 december 2023 · IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 · Persbericht

7 november 2023 · IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update · Persbericht

1 november 2023 · IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference · Persbericht

27 oktober 2023 · IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

27 oktober 2023 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

Mijn selecties